Andrew Stewart, MD
img_Andrew Stewart
PROFESSOR | Medicine, Endocrinology, Diabetes and Bone Disease
Research Topics
Autoimmunity, Cell Biology, Cell Cycle, Cell Division, Cellular Differentiation, DNA Replication, Diabetes, Gene Discovery, Gene Expressions, Gene Therapy, Genomics, Growth Factors and Receptors, Hormones, Immunosuppression, Insulin, Knockout Mice, Obesity, Oncogenes, Phosphorylation, Protein Kinases, Proteomics, Receptors, Transgenic Mice, Transplantation, Tumor Suppressor Genes
Multi-Disciplinary Training Area
Genetics and Genomic Sciences [GGS]
Dr. Andrew Stewart is the Scientific Director of the Diabetes, Obesity and Metabolism Institute (DOMI). He an authority on human insulin-producing pancreatic beta cell replication and regeneration for people with diabetes.  His research focuses on understanding and developing novel therapies for inducing human beta cell regeneration, from gene therapy to small molecule drug discovery.  His group was the first to demonstrate that growth factors could drive beta cell replication in vivo in mammals, and also improve glucose control in living animals.  His group was also the first to carefully define cell cycle control in the rodent and human beta cell. They were also the first to report that small molecule drugs that inhibit the enzyme DYRK1A are able to induce human beta cells to replicate, and to reverse diabetes in vivo in mice transplanted with human beta cells.  He is actively involved in developing next-generation DYRK1A inhibitors for human diabetes, and understanding why human beta cells are so refractory to replication. His work has been continually supported by the NIH/NIDDK and the JDRF.

Please visit the Stewart Laboratory.

MD, Columbia University, College of Physicians and Surgeons

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Dr. Stewart did not report having any of the following types of financial relationships with industry during 2022 and/or 2023: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.